Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

THERANEXUS : publishes its cash position as of September 30, 2020

10/16/2020 | 10:19am EST

Lyon - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its cash position as at 30 September 2020.

Total available funds on 30 September 2020 stand at EUR11.9 M, compared with EUR11.3 M (pro forma cash of EUR13.3 M) on 30 June 2020, reflecting rigorous expenditure management.

The coming quarters will notably be marked by a ramp-up in preclinical studies conducted to confirm the safety of drug candidate BBDF-101 in Batten disease, with related planned expenditure estimated at roughly EUR4 M over the coming 12 months.

Moreover, Theranexus announces that it is currently in active discussions with potential industrial partners to continue clinical development of THN102 for Parkinson's disease. In today's health and economic climate, the Company's goal is still to conclude a partnership agreement in the coming months and ideally by the end of 2020.

ABOUT THERANEXUS

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as 'glial cells') in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.

The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.

Contact:

Tel: 33 (0)6 07 76 82 83

Email: fportejoie@fp2com.fr

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about THERANEXUS
11/20THERANEXUS : - The Food And Drug Administration issues a favorable opinion on th..
AQ
11/20THERANEXUS : The Food And Drug Administration (FDA) issues a favorable opinion o..
PU
11/19THERANEXUS : The food and drug administration (fda) issues a favorable opinion o..
AN
11/05THERANEXUS : - Presentation of the results of the phase 1b clinical study with T..
AQ
11/04THERANEXUS : Presentation of the results of the phase 1b clinical study of THN20..
PU
11/04THERANEXUS : Presentation of the results of the phase ib clinical study of thn20..
AN
10/22THERANEXUS : TTHERANEXUS and the BBDF Foundation Obtain Orphan Drug Status in Eu..
AQ
10/21THERANEXUS : and BBDF obtain European "orphan medicinal product" designation for..
PU
10/16THERANEXUS : publishes its cash position as of September 30, 2020
AQ
10/15THERANEXUS : 3rd quarter earnings
CO
More news
Financials
Sales 2020 25,4 M 30,6 M 30,6 M
Net income 2020 20,1 M 24,2 M 24,2 M
Net cash 2020 58,0 M 70,0 M 70,0 M
P/E ratio 2020 3,28x
Yield 2020 -
Capitalization 67,2 M 81,0 M 81,1 M
EV / Sales 2020 0,36x
EV / Sales 2021 1,68x
Nbr of Employees 17
Free-Float 57,4%
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 23,15 €
Last Close Price 18,15 €
Spread / Highest target 44,9%
Spread / Average Target 27,5%
Spread / Lowest Target 10,2%
EPS Revisions
Managers
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial & Administrative Officer
Mathieu Bernard Mari Charveriat Director, Chief Scientific Officer & Deputy CEO
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS472.37%77
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915